Results 291 to 300 of about 3,163,010 (367)

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long‐Term Outcomes in a Prospective, Single‐Arm Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Two randomized trials for patients with diffuse systemic sclerosis (SSc) demonstrated an overall survival (OS) and event‐free survival (EFS) advantage of autologous hematopoietic stem cell transplantation (AHSCT) using CD34+ selected peripheral blood stem cells (PBSCs) compared with monthly cyclophosphamide (CY).
George E. Georges   +16 more
wiley   +1 more source

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera   +14 more
wiley   +1 more source

Severe myelosuppression and alopecia after thiopurine initiation in a patient with NUDT15 deficiency

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Thiopurines are a class of immunosuppressant and antineoplastic agents. They are widely used in the treatment of inflammatory bowel disease, haematological malignancies and autoimmune diseases, but can cause significant toxicity. Inherited gene mutations are now recognized as independent risk factors for severe adverse drug reactions to thiopurines ...
Annie Siyu Wu   +3 more
wiley   +1 more source

Recent Developments and Challenges in the Treatment of Acute Leukemia and Myelodysplastic Syndromes: A Systematic Review. [PDF]

open access: yesCureus
Rafiq N   +11 more
europepmc   +1 more source

Is Enhancer Function Driven by Protein–Protein Interactions? From Bacteria to Leukemia

open access: yesBioEssays, EarlyView.
Enhancers are key regulatory elements that are conceptually conserved from bacteria to humans. Enhancer dysregulation is common in cancers, including leukemia. We argue that highly specific protein–protein interactions, including transcription factors, mediate enhancer‐promoter proximity to allow enhancer‐bound factors to directly act on RNA polymerase
Nicholas T. Crump, Thomas A. Milne
wiley   +1 more source

Home - About - Disclaimer - Privacy